Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Phase 2 trial of brentuximab vedotin plus AVD for non-bulky limited-stage Hodgkin lymphoma

Jeremy Abramson • 2 Jun 2015
ASCO 2015
Hodgkin Lymphoma Antibodies Brentuximab vedotin Dacarbazine Doxorubicin Vinblastine

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicenter Phase 2 study that is evaluating brentuximab vedotin, an antibody-drug conjugate, plus doxorubicin (adriamycin), vinblastine and dacarbazine (AVD) for the treatment of patients with non-bulky limited-stage classical Hodgkin lymphoma.

More from Jeremy Abramson

2:52
Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies
Jeremy Abramson • 12 Dec 2022
2:05
Emerging treatment strategies for patients with high-risk follicular lymphoma
Jeremy Abramson • 12 Dec 2022
3:23
Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma
Jeremy Abramson • 12 Dec 2022
2:46
TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL
Jeremy Abramson • 12 Dec 2022

Related Videos

2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:50
Results of the EuroNet-PHL-C1 trial: omission of radiotherapy in children and adolescents with cHL
Christine Mauz-Körholz • 8 Dec 2023
1:17
KEYNOTE-667: pembrolizumab plus COPDAC-28 for high-risk cHL with slow early response to OEPA
Christine Mauz-Körholz • 8 Dec 2023
0:52
Managing late effects of treatment in pediatric patients with Hodgkin lymphoma
Christine Mauz-Körholz • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals